 | Krzysztof Sladek |
Prominent publications by Krzysztof Sladek
BACKGROUND: A hallmark of idiopathic pulmonary fibrosis is the excess accumulation of extracellular matrix in the lungs. Degradation of extracellular matrix generates free-circulating protein fragments called neoepitopes. The aim of the INMARK trial was to investigate changes in neoepitopes as predictors of disease progression in patients with idiopathic pulmonary fibrosis and the effect of nintedanib on these biomarkers.
METHODS: In this randomised, double-blind, placebo-controlled ...
| Also Ranks for: Nintedanib Patients | pulmonary fibrosis | extracellular matrix | 12 weeks | placebo rate |
Antihypertensive Efficacy and Safety of Manidipine versus Amlodipine in Elderly Subjects with Isolated Systolic Hypertension
[ PUBLICATION ]
Background and objective: Isolated systolic hypertension (ISH) affects 10–20% of the elderly population and is strongly related to the risk of cardiovascular events. Elevated systolic BP values are primarily caused by reduced large vessel compliance with a consequent increase in total peripheral resistance. Vasodilating drugs, such as calcium channel antagonists, have proven to be effective in controlling ISH in elderly patients. This study set out to compare the antihypertensive ...
| Also Ranks for: Manidipine Amlodipine | mm hg | calcium channel | efficacy safety | antihypertensive agents |
Krzysztof Sladek:Expert Impact
Concepts for whichKrzysztof Sladekhas direct influence:Nintedanib patients, Patients nintedanib, Idiopathic pulmonary fibrosis, Nintedanib placebo, Manidipine amlodipine, Pulmonary fibrosis, Placebo rate, Baseline fvc.
Krzysztof Sladek:KOL impact
Concepts related to the work of other authors for whichfor which Krzysztof Sladek has influence:Idiopathic pulmonary fibrosis, 55 years, Nintedanib patients, Progressive phenotype, Hub genes, Fvc decline, Lung fibroblasts.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |